We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





COVID-19 Rapid Antigen Test Provides End-to-End Digital Screening Solution

By LabMedica International staff writers
Posted on 03 Jun 2021
Print article
Image: PixoTest POCT COVID-19 Antigen Test (Photo courtesy of iXensor)
Image: PixoTest POCT COVID-19 Antigen Test (Photo courtesy of iXensor)
A new COVID-19 antigen test provides a full end-to-end digital screening solution to prevent further outbreaks.

iXensor’s (Taipei, Taiwan) PixoTest POCT COVID-19 Antigen Test has received the CE-IVD mark. The iXensor’s PixoTest solution comprises a palm-sized analyzer that reads test results accurately, a digital health pass App, an Admin App, and a HIPAA-grade health management web portal. The fully digitized testing and reporting design shortens the test-to-report time to 15 minutes. In addition to overcoming the lab testing limitations, the solution allows for scaling in large screening settings, thereby enabling business continuity and reopening.

With the PixoTest POCT Analyzer reading test results objectively, healthcare organizations and corporations can minimize the risks of having false-negative cases compared to rapid tests interpreted by human eyes. The analyzer transmits test results simultaneously to the PixoHealth Pass App users via an encrypted QR code. The digital health pass also records App users’ vaccination certificates, helping free movement in the upcoming summer holiday season. The PixoHealth Pass Admin App is designed for organizations to verify the authenticity of PixoTest test results with one simple scan. The admin app protects organizations’ safety amidst the pandemic by validating the cheat-proof, encrypted results shown on PixoHealth Pass App.

“We are deploying iXensor’s core PixoTech technology to develop the smartphone-based self-test that can perform COVID-19 testing and tracking, anywhere at any time,” said Dr. Peter Fitzgerald, Chairman of iXensor and Emeritus Professor of Medicine School at Stanford University. “I believe having COVID-19 at-home test will drastically cut many transmission paths to stop the pandemic.”

Related Links:
iXensor

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.